KAREN RABIN to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications KAREN RABIN has written about Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
2.894
-
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov; 41(11):1243-6.
Score: 0.298
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
Score: 0.213
-
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.
Score: 0.201
-
Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome. Blood Adv. 2023 08 08; 7(15):3928-3931.
Score: 0.194
-
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. Leukemia. 2023 06; 37(6):1375-1378.
Score: 0.189
-
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2022 03; 36(3):648-655.
Score: 0.172
-
Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
Score: 0.171
-
Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
Score: 0.171
-
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021 05 01; 39(13):1437-1447.
Score: 0.162
-
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020 08 10; 38(23):2628-2638.
Score: 0.156
-
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
Score: 0.155
-
Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019 Oct; 48:49-57.
Score: 0.149
-
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
Score: 0.141
-
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
Score: 0.141
-
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017 06 22; 129(25):3352-3361.
Score: 0.125
-
The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
Score: 0.114
-
Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 2015 Jan-Feb; 208(1-2):1-18.
Score: 0.106
-
Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. J Natl Cancer Inst. 2019 12 01; 111(12):1350-1357.
Score: 0.038